Minor extended-spectrum β-lactamases

Expert Rev Anti Infect Ther. 2010 Nov;8(11):1251-8. doi: 10.1586/eri.10.119.

Abstract

Over the last few decades, various extended-spectrum β-lactamases (ESBLs), which are remotely related to the classical TEM and SHV families, have emerged. Among these, CTX-M, VEB and PER variants are of particular interest due to their widespread dissemination. This article will focus on these emerging ESBLs. CTX-M was first identified from an Escherichia coli strain in Germany and since then, a rapidly growing family of ESBLs has formed worldwide. There are now more than 90 CTX-M variants. VEB-1 ESBL is widespread in Southeast Asia. It was first identified in an E. coli strain isolated from a Vietnamese boy in 1996. After the initial discovery, it spread to other species. PER-1, now reported from various continents, was restricted to Turkish hospitals for years after the first identification in a strain of Pseudomonas aeruginosa in 1993. The worldwide dissemination of ESBLs is a healthcare crisis that deserves special attention.

Publication types

  • Review

MeSH terms

  • Drug Resistance, Bacterial
  • Drug Resistance, Multiple, Bacterial
  • Enterobacteriaceae / drug effects
  • Enterobacteriaceae / enzymology*
  • Enterobacteriaceae / metabolism
  • Escherichia coli Proteins
  • Gram-Negative Bacteria / drug effects
  • Gram-Negative Bacteria / enzymology*
  • Humans
  • Microbial Sensitivity Tests
  • Pseudomonas aeruginosa / drug effects
  • Pseudomonas aeruginosa / enzymology
  • beta-Lactamase Inhibitors
  • beta-Lactamases / classification
  • beta-Lactamases / genetics
  • beta-Lactamases / metabolism*

Substances

  • Escherichia coli Proteins
  • beta-Lactamase Inhibitors
  • beta-lactamase CTX-2
  • beta-lactamase PER-1
  • beta-lactamase TEM-3
  • beta-lactamase VEB-1, E coli
  • beta-Lactamases